However, the existence of FDA-approved β3-AR agonists such as mirabegron and vibegron, currently indicated for the treatment of overactive bladder in adults, opens intriguing perspectives for potential pharmacological repurposing. This evidence concerns the gene ADRB3 and overactive bladder.